451 related articles for article (PubMed ID: 28407394)
1. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R;
Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394
[TBL] [Abstract][Full Text] [Related]
2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
Hsiao SM; Lin HH; Kuo HC
PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome.
Balzarro M; Rubilotta E; Braga A; Bassi S; Processali T; Artibani W; Serati M
Eur J Obstet Gynecol Reprod Biol; 2018 Jun; 225():228-231. PubMed ID: 29753213
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.
Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
J Urol; 2013 Jun; 189(6):2186-93. PubMed ID: 23246476
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
Jiang YH; Ong HL; Kuo HC
Neurourol Urodyn; 2017 Jan; 36(1):142-147. PubMed ID: 26417884
[TBL] [Abstract][Full Text] [Related]
9. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs as potential biomarkers to predict the risk of urinary retention following intradetrusor onabotulinumtoxin-A injection.
Chermansky CJ; Kadow BT; Kashyap M; Tyagi P
Neurourol Urodyn; 2018 Jan; 37(1):99-105. PubMed ID: 28493606
[TBL] [Abstract][Full Text] [Related]
13. Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.
Kanagarajah P; Ayyathurai R; Caruso DJ; Gomez C; Gousse AE
Int Urol Nephrol; 2012 Feb; 44(1):91-7. PubMed ID: 21643644
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).
Tincello DG; Kenyon S; Abrams KR; Mayne C; Toozs-Hobson P; Taylor D; Slack M
Eur Urol; 2012 Sep; 62(3):507-14. PubMed ID: 22236796
[TBL] [Abstract][Full Text] [Related]
15. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.
Nitti VW; Ginsberg D; Sievert KD; Sussman D; Radomski S; Sand P; De Ridder D; Jenkins B; Magyar A; Chapple C;
J Urol; 2016 Sep; 196(3):791-800. PubMed ID: 27038769
[TBL] [Abstract][Full Text] [Related]
16. Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.
Jiang YH; Kuo HC
Neurourol Urodyn; 2017 Feb; 36(2):338-343. PubMed ID: 26575613
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of an alternative onabotulinumtoxinA injection paradigm for refractory overactive bladder.
MacDiarmid S; Glazier DB; McCrery RJ; Kennelly MJ; Nelson M; Ifantides KB; McCammon KA
Neurourol Urodyn; 2024 Jan; 43(1):31-43. PubMed ID: 37746881
[TBL] [Abstract][Full Text] [Related]
18. Can botox improve night-time overactive bladder symptoms in women?
Miotla P; Cartwright R; Futyma K; Bogusiewicz M; Skorupska K; Winkler I; Rechberger T
Neurourol Urodyn; 2017 Mar; 36(3):648-652. PubMed ID: 26915654
[TBL] [Abstract][Full Text] [Related]
19. Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical Trial.
McCammon K; Gousse A; Kohan A; Glazier D; Gruenenfelder J; Bai Z; Patel A; Hale D
Female Pelvic Med Reconstr Surg; 2021 Jul; 27(7):450-456. PubMed ID: 32665528
[TBL] [Abstract][Full Text] [Related]
20. Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?
Kuo YC; Kuo HC
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
